Abstract
Abstract
Introduction: Statin-associated anti-HMGCR immune-mediated necrotizing myopathy is a rare autoimmune myopathy characterized by progressive proximal weakness and persistent muscle enzyme elevation despite statin discontinuation. Although glucocorticoids are commonly used as initial therapy, biochemical and functional responses may be discordant. Few published cases document this dissociation through serial paired creatine kinase (CK) and standardized strength measurements. This case contributes such data and supports early IVIG escalation when disability persists despite glucocorticoid therapy.
Case Description: We present the case of a 71-year-old woman on chronic statin therapy who developed several weeks of progressive proximal weakness with marked creatine kinase elevation. Evaluation demonstrated positive anti-HMGCR antibodies, diffuse symmetric muscle edema on thigh magnetic resonance imaging, electromyographic findings consistent with inflammatory myopathy, and necrotizing myopathy on biopsy, fulfilling the 2018 ENMC classification criteria for anti-HMGCR IMNM. High-dose prednisone led to partial biochemical improvement; at six-week follow-up, CK had declined to 1,683 U/L while hip flexion strength had worsened to MRC grade 2/5, illustrating a quantified CK-strength dissociation. IVIG was initiated at 2 g/kg per cycle every 4 weeks. Progressive strength recovery to 5/5 bilaterally and CK normalization were achieved at one year.
Conclusion: This case provides a prospectively documented, quantified illustration of the CK-strength dissociation, a pattern underreported in the literature. The use of CK alone may be an unreliable marker of disease burden. Strength should be assessed independently at each visit. Early IVIG escalation should be considered when meaningful weakness persists despite glucocorticoid therapy.
Recommended Citation
Tou, Leila C.; Madrid-Calles, Juan P.; Aymerich, Raquel S.; and Koraym, Sarah
(2026)
"Anti-HMGCR Immune-Mediated Necrotizing Myopathy: Persistent Weakness Despite Glucocorticoids and Recovery After IVIG,"
Journal of Community Hospital Internal Medicine Perspectives: Vol. 16:
Iss.
6, Article 19.
DOI: https://doi.org/10.55729/2000-9666.1660
Available at:
https://scholarlycommons.gbmc.org/jchimp/vol16/iss6/19
DOI
10.55729/2000-9666.1660
